Directorate Change

RNS Number : 1121B
Osmetech PLC
12 August 2008

12 August 2008
Osmetech plc ('Osmetech' or the 'Company')
Board changes

Osmetech plc (OMH.L), the fast developing international molecular diagnostics business announces that Daryl Jay Faulkner, 59, will join
the Company as Non-Executive Chairman with immediate effect. Gordon Hall, the Company's current Chairman will step down but will remain on
the Board as a Non-Executive Director.

Mr. Faulkner brings to Osmetech extensive experience in building and leading large businesses in the molecular diagnostics, life
sciences and medical device industries. Most recently, he was President and Chief Executive Officer of molecular diagnostics company,
Digene Corporation, and a member of its board of directors prior to the $1.6 billion sale to Qiagen N.V. in 2007. In the past year Mr.
Faulkner has continued to provide consulting services to Qiagen related to the integration process after the merger.

Prior to joining Digene, Mr. Faulkner spent eight years at Invitrogen Corp., a life sciences company with more than $1 billion in
revenues, serving in several senior level capacities, including Senior Vice President/General Manager for Strategic Business Units, Senior
Vice President for Europe and Senior Vice President for International Operations. Previously, Mr. Faulkner served for 15 years in a variety
of roles at Abbott Laboratories Inc., a diversified healthcare company.

Gordon Hall, Non-Executive Director of Osmetech said: "We are delighted to welcome Daryl Faulkner as our new Chairman for the next stage
in the Company's development. We are very excited by the growth prospects ahead of us and should benefit greatly from Daryl's considerable
expertise and directly relevant experience in the molecular diagnostics industry. It is a testimony to the strength of our technology,
product offerings and market positioning that someone of Daryl's calibre has elected to join Osmetech"

Daryl Faulkner said: "I look forward to working with the Osmetech team in developing the tremendous opportunities it has to grow and
build value for shareholders. The Company is at an exciting stage in its development and well placed to take advantage of the anticipated
growth in the rapidly growing molecular diagnostics market. It has a strong combination of technology, FDA cleared product and the people
with the experience and talent necessary to drive the business forward to the next level."

Osmetech also announces that Bruce Huebner has retired from the Company and consequently resigned as a Director of the Company. The
Board of Directors of Osmetech would like to thank Bruce for his contribution to the development of the Group's molecular diagnostics
business during his time with Osmetech since the acquisition of the Clinical Micro Sensors, Inc. from Motorola, Inc. in 2005.

Osmetech plc +44 (0)207 849 6027
James White, Chief Executive Officer
David Sandilands, Chief Financial Officer

Madano Partnership +44 (0) 207 593 4000
Matthew Moth, Mark Way
www.madano.com

Canacccord Adams Limited +44 (0) 207 050 6500
Robert Finlay
L. Warren Pimm

Save as disclosed below, there are no further disclosures required to be made pursuant to schedule 2, paragraph (g) of the AIM Rules for
Companies.

Daryl Faulkner is currently a director of the Maryland Biotech Council and during the past 5 years has also been a director of Digene
Corporation and Nanostream, Inc., Nanostream Inc, a private biotechnology tools and analysis equipment company, closed its operations on
March 14, 2008 and is currently being voluntarily wound up with the expectation that it will discharge all of its liabilities in full. Mr.
Faulkner was the Non-Executive Chairman of Nanostream until the company was recapitalized in 2006, after which he became a Director.

About Osmetech plc
www.osmetech.com

Osmetech plc is a public company listed on the AIM market of the London Stock Exchange. The company is a fast developing, international
diagnostics business with operations in Boston and Pasadena in the US, serving the high growth molecular diagnostic market targeting
hospitals and reference laboratories. Osmetech has rights to a strong portfolio of over 200 issued and pending patents and has launched its
first generation eSensor 4800 platform, an electrochemistry-based array system, together with an FDA cleared in vitro diagnostic test for
Cystic Fibrosis carrier detection. In July 2008, Osmetech received FDA clearance for its second generation eSensor XT-8 molecular
diagnostics platform and Warfarin Sensitivity Test.

This information is provided by RNS
The company news service from the London Stock Exchange

END

BOAPBMBTMMMBTMP

Osmetech (LSE:OMH)
Historical Stock Chart
From Jun 2024 to Jul 2024